Hypermetabolic Axillary Lymph Nodes Associated with COVID-19 Vaccination in Breast Cancer Management.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Cengiz Taşçı, Ahmet Dirican, Ethem Murat Sözbilen, Fatma Seher Pehlivan, Selim Serter
{"title":"Hypermetabolic Axillary Lymph Nodes Associated with COVID-19 Vaccination in Breast Cancer Management.","authors":"Cengiz Taşçı,&nbsp;Ahmet Dirican,&nbsp;Ethem Murat Sözbilen,&nbsp;Fatma Seher Pehlivan,&nbsp;Selim Serter","doi":"10.4274/mirt.galenos.2023.82712","DOIUrl":null,"url":null,"abstract":"<p><p>A 42-year-old female patient diagnosed with invasive ductal breast ca underwent <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) scan for staging, 1.5 cm diameter hypermetabolic lesion was observed in the lower inner quadrant of the right breast that was compatible with primary tumor [maximum standardized uptake value (SUV<sub>max</sub>): 10.5]. No pathological <sup>18</sup>F-FDG uptake was observed in lymph nodes whose fatty hilum was seen in the right axilla. However, in the left axilla and left deep axilla, hypermetabolic lymph nodes with a maksimum diameter of 19 mm and fatty hilum were observed (SUV<sub>max</sub>: 8.0). In a detailed CT evaluation, these lymph nodes have thicker walls than the ones in the right axilla. The patient was questioned again and coronavirus disease-2019 (COVID-19) vaccination history (with BNT162b2, COVID-19 mRNA vaccine) was determined that was administrated to the left arm 5 days ago. Tru-cut biopsy was performed from the left aksillary lymph nodes and proved to be reactive lymphoid tissue and there was no primary or metastatic tumor in these axillary lymph node tissues. The patient was given neoadjuvant chemotherapy 4.5 months after the first <sup>18</sup>F-FDG PET/CT, and the second was performed for the treatment response evaluation. Significant regression was determined from the findings. The patient underwent right total mastechtomy. She was being followed up with adjuvant chemotherapy and radiotherapy. In conclusion, hypermetabolic lymph nodes in the axillas should be interrogated for vaccination in patients with breast cancer. Hypermetabolic lymph nodes observed on the same side of the vaccinated arm in the <sup>18</sup>F-FDG PET/CT scan may be related to vaccine-induced reactive lymph node enlargement. Lymph node metastasis may be excluded, especially if there are hypermetabolic lymph nodes with preserved fatty hilum in the contralateral axilla on the same side as the vaccinated arm. Active lymph nodes reactive to the vaccine become inactive after a while.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/0f/MIRT-32-181.PMC10284176.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2023.82712","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

A 42-year-old female patient diagnosed with invasive ductal breast ca underwent 18F-fluorodeoxyglucose (FDG) positron emission tomography/ computed tomography (PET/CT) scan for staging, 1.5 cm diameter hypermetabolic lesion was observed in the lower inner quadrant of the right breast that was compatible with primary tumor [maximum standardized uptake value (SUVmax): 10.5]. No pathological 18F-FDG uptake was observed in lymph nodes whose fatty hilum was seen in the right axilla. However, in the left axilla and left deep axilla, hypermetabolic lymph nodes with a maksimum diameter of 19 mm and fatty hilum were observed (SUVmax: 8.0). In a detailed CT evaluation, these lymph nodes have thicker walls than the ones in the right axilla. The patient was questioned again and coronavirus disease-2019 (COVID-19) vaccination history (with BNT162b2, COVID-19 mRNA vaccine) was determined that was administrated to the left arm 5 days ago. Tru-cut biopsy was performed from the left aksillary lymph nodes and proved to be reactive lymphoid tissue and there was no primary or metastatic tumor in these axillary lymph node tissues. The patient was given neoadjuvant chemotherapy 4.5 months after the first 18F-FDG PET/CT, and the second was performed for the treatment response evaluation. Significant regression was determined from the findings. The patient underwent right total mastechtomy. She was being followed up with adjuvant chemotherapy and radiotherapy. In conclusion, hypermetabolic lymph nodes in the axillas should be interrogated for vaccination in patients with breast cancer. Hypermetabolic lymph nodes observed on the same side of the vaccinated arm in the 18F-FDG PET/CT scan may be related to vaccine-induced reactive lymph node enlargement. Lymph node metastasis may be excluded, especially if there are hypermetabolic lymph nodes with preserved fatty hilum in the contralateral axilla on the same side as the vaccinated arm. Active lymph nodes reactive to the vaccine become inactive after a while.

Abstract Image

Abstract Image

Abstract Image

高代谢腋窝淋巴结与COVID-19疫苗接种在乳腺癌管理中的相关性
确诊为浸润性导管性乳腺的42岁女性患者行18f -氟氧葡萄糖(FDG)正电子发射断层扫描/ PET/CT扫描进行分期,右侧乳腺下内象限见直径1.5 cm的高代谢病变,与原发肿瘤相适应[最大标准化摄取值(SUVmax): 10.5]。右腋窝脂肪门淋巴结未见病理性18F-FDG摄取。左腋窝和左腋窝深部可见最大直径19 mm的高代谢淋巴结和脂肪门(SUVmax: 8.0)。在详细的CT评估中,这些淋巴结的壁比右腋窝的淋巴结壁厚。再次对患者进行问询,并确定5 d前给予左臂的冠状病毒病-2019 (COVID-19)疫苗接种史(接种BNT162b2、COVID-19 mRNA疫苗)。从左侧腋窝淋巴结进行了真切活检,证实是反应性淋巴组织,这些腋窝淋巴结组织中没有原发性或转移性肿瘤。患者在第一次18F-FDG PET/CT检查后4.5个月给予新辅助化疗,第二次进行治疗反应评估。根据研究结果确定了显著的回归。患者行右侧全乳切除术。她正在接受辅助化疗和放疗。总之,乳腺癌患者应检查腋部高代谢淋巴结,以便接种疫苗。18F-FDG PET/CT扫描在接种疫苗的同侧观察到的高代谢淋巴结可能与疫苗诱导的反应性淋巴结肿大有关。淋巴结转移可以排除,特别是如果在接种疫苗的手臂同一侧的对侧腋窝存在高代谢淋巴结并保留脂肪门。对疫苗有反应的活跃淋巴结在一段时间后变得不活跃。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Imaging and Radionuclide Therapy
Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信